Neurotrophic Factors, Tight Junction Proteins, and Cytokines in IBS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the role of neurotrophic factors (NGF, GDNF, TRPV-1), to quantity tight junction proteins (ZO-1, occludin, claudin) and cytokines (IL-8, TNF-a, IL-1b) in the colonic mucosa of IBS patients and also clarify sex differences in the pathophysiology of IBS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Expression of the Ionotropic Glutamate Receptors in Colon of IBS

NCT02512146

Irritable Bowel Syndrome

UNKNOWN

Is There Any Correlation Between Plasmatic Zonulin and Expression of Intestinal Tight Junction Proteins in IBS Patients?

NCT02877654

Irritable Bowel Syndrome

COMPLETED NA

Assessment of Small Intestinal Bowel Epithelial Gaps in Irritable Bowel Syndrome

NCT01632488

Irritable Bowel Syndrome Inflammatory Bowel Disease

UNKNOWN

Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome

NCT05819281

Irritable Bowel Syndrome

UNKNOWN PHASE2

Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients

NCT02550704

Irritable Bowel Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome Tight Junction Alteration Pathophysiology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBS group

Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.

Group Type SHAM_COMPARATOR

colonoscopic mucosal biopsy

Intervention Type PROCEDURE

colonoscopic mucosal biopsy was undertaken for every participant

Control group

Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.

Group Type ACTIVE_COMPARATOR

colonoscopic mucosal biopsy

Intervention Type PROCEDURE

colonoscopic mucosal biopsy was undertaken for every participant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

colonoscopic mucosal biopsy

colonoscopic mucosal biopsy was undertaken for every participant

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Control group Those who were between 18 and 80 years old and did not have any abnormalities in colonoscopy
* Irritable bowel syndrome group Patients who diagnosed as irritable bowel syndrome according to the ROME III criteria